Reversible sideroblastic anemia associated with the tetracycline analogue COL-3

Authors
Rudek, MA Horne, M Figg, WD Dahut, W Dyer, V Pluda, JM Reed, E
Citation
Ma. Rudek et al., Reversible sideroblastic anemia associated with the tetracycline analogue COL-3, AM J HEMAT, 67(1), 2001, pp. 51-53
Citations number
13
Categorie Soggetti
Hematology,"Cardiovascular & Hematology Research
Journal title
AMERICAN JOURNAL OF HEMATOLOGY
ISSN journal
03618609 → ACNP
Volume
67
Issue
1
Year of publication
2001
Pages
51 - 53
Database
ISI
SICI code
0361-8609(200105)67:1<51:RSAAWT>2.0.ZU;2-U
Abstract
Eight of 35 patients with cancer receiving COL-3, a tetracycline derivative with antiangiogenic properties, developed anemia while on treatment. All o f these patients were enrolled on an approved Phase I clinical trial at the National Cancer Institute, Three of these patients had bone marrow examina tions that revealed ringed sideroblasts, This paper describes these cases. Am. J. Hematol, 87:51-53, 2001. Published 2001 Wiley-Liss, Inc.